title: Clinical outcome after crush versus culotte stenting of coronary artery bifurcation lesions: the Nordic Stent Technique Study 36-month follow-up results.
abstract: OBJECTIVE
  The aim of the study was to compare long-term follow-up results of crush versus culotte stent techniques in coronary bifurcation lesions.
  
  
  BACKGROUND
  The randomized Nordic Stent Technique Study showed similar 6-month clinical and 8-month angiographic results with the crush and culotte stent techniques of de novo coronary artery bifurcation lesions using sirolimus-eluting stents. Here, we report the 36-month efficacy and safety of the Nordic Stent Technique Study.
  
  
  METHODS
  A total of 424 patients with a bifurcation lesion were randomized to stenting of both main vessel and side branch with the crush or the culotte technique and followed for 36 months. Major adverse cardiac events-the composite of cardiac death, myocardial infarction, stent thrombosis, or target vessel revascularization-were the primary endpoint.
  
  
  RESULTS
  Follow-up was complete for all patients. At 36 months, the rates of the primary endpoint were 20.6% versus 16.7% (p = 0.32), index lesion restenosis 11.5% versus 6.5% (p = 0.09), and definite stent thrombosis 1.4% versus 4.7% (p = 0.09) in the crush and the culotte groups, respectively.
  
  
  CONCLUSIONS
  At 36-month follow-up, the clinical outcomes were similar for patients with coronary bifurcation lesions treated with the culotte or the crush stent technique. (Nordic Bifurcation Study. How to Use Drug Eluting Stents [DES] in Bifurcation Lesions? NCT00376571).
authors.affiliation: Division of Cardiology, Department of Medicine, Oulu University Hospital, Oulu, Finland. Electronic address: kari.kervinen@ppshp.fi.
authors.forename: Kari
authors.initials: K
authors.lastname: Kervinen
authors.forename: Matti
authors.initials: M
authors.lastname: Niemelä
authors.forename: Hannu
authors.initials: H
authors.lastname: Romppanen
authors.forename: Andrejs
authors.initials: A
authors.lastname: Erglis
authors.forename: Indulis
authors.initials: I
authors.lastname: Kumsars
authors.forename: Michael
authors.initials: M
authors.lastname: Maeng
authors.forename: Niels R
authors.initials: NR
authors.lastname: Holm
authors.forename: Jens F
authors.initials: JF
authors.lastname: Lassen
authors.forename: Pål
authors.initials: P
authors.lastname: Gunnes
authors.forename: Sindre
authors.initials: S
authors.lastname: Stavnes
authors.forename: Jan S
authors.initials: JS
authors.lastname: Jensen
authors.forename: Anders
authors.initials: A
authors.lastname: Galløe
authors.forename: Inga
authors.initials: I
authors.lastname: Narbute
authors.forename: Dace
authors.initials: D
authors.lastname: Sondore
authors.forename: Evald H
authors.initials: EH
authors.lastname: Christiansen
authors.forename: Jan
authors.initials: J
authors.lastname: Ravkilde
authors.forename: Terje K
authors.initials: TK
authors.lastname: Steigen
authors.forename: Jan
authors.initials: J
authors.lastname: Mannsverk
authors.forename: Per
authors.initials: P
authors.lastname: Thayssen
authors.forename: Knud Nørregaard
authors.initials: KN
authors.lastname: Hansen
authors.forename: Steffen
authors.initials: S
authors.lastname: Helqvist
authors.forename: Saila
authors.initials: S
authors.lastname: Vikman
authors.forename: Rune
authors.initials: R
authors.lastname: Wiseth
authors.forename: Jens
authors.initials: J
authors.lastname: Aarøe
authors.forename: Jari
authors.initials: J
authors.lastname: Jokelainen
authors.forename: Leif
authors.initials: L
authors.lastname: Thuesen
mesh_terms: D000368:Aged; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D023903:Coronary Restenosis / Q000209:etiology; D003328:Coronary Thrombosis / Q000209:etiology; D054855:Drug-Eluting Stents; D005260:Female; D005387:Finland; D006801:Humans; D007844:Latvia; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation* / Q000379:methods* / Q000401:mortality; D011474:Prosthesis Design; D012307:Risk Factors; D012537:Scandinavian and Nordic Countries; D020123:Sirolimus / Q000008:administration & dosage*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D020123:Sirolimus
keywords: FKBD; LM; MACE; MI; PCI; SB; ST; TLR; angioplasty; balloon; bifurcation lesions; coronary artery disease; drug-eluting stents; final kissing balloon dilation; left main coronary artery; major adverse cardiac events; myocardial infarction; percutaneous coronary intervention; restenosis; side branch; stent thrombosis; target lesion revascularization